相关实验视频

Updated: Sep 18, 2025

Role of Diffusion MRI Tractography in Endoscopic Endonasal Skull Base Surgery

Role of Diffusion MRI Tractography in Endoscopic Endonasal Skull Base Surgery

Published on: July 5, 2021

中枢神经细胞瘤的治疗方法

Anna Michel^1,2,3, Jan Rodemerk^1,2,3, Laurèl Rauschenbach^1,2,3,4

¹Department of Neurosurgery and Spine Surgery, University Hospital Essen, University Duisburg-Essen, Hufelandstraße 55, 45147 Essen, Germany.

|June 26, 2025

概括

总体切除是中央神经细胞瘤 (CNs),罕见的大脑瘤的建议一线治疗方法. 辅助放射治疗是为了进展,而化疗是为了进展.

科学领域:

神经瘤学神经瘤学
神经外科神经外科
病理学病理学病理学

背景情况:

中枢神经细胞瘤 (CNs) 是一种罕见的中枢神经系统二级瘤 (内瘤的0.1-0.5%).
常常存在的CN与水脑并具有一般良性的临床过程.
本研究提供了对CN的治疗方法的全面分析.

研究的目的:

分析中枢神经细胞瘤的手术和辅助治疗方法.
评估CN患者的临床结果和无复发生存期.

主要方法:

从2013年至2023年期间,在11名患者中进行了微手术瘤切除.
评估临床数据,成像,组织学和治疗结果.
对Ki67扩散指数和无复发生存率的评估.

主要成果:

腹腔内瘤是最常见的 (72.7%);头痛和视力障碍是主要症状.
中位数无复发生存时间为38.0个月;5名患者患有显著的术后并发症.
九名患者的Ki67指数>3%;所有患者在治疗后表现出症状改善.

结论:

总体切除是建议的CN的第一线治疗方法,包括非典型的病例.
辅助放射治疗适用于瘤进展或复发.
辅助化疗的作用是不确定的,但可能有利于高扩散的CN.

关键词:

作为辅助剂的放射治疗.非典型的中央神经细胞瘤中央神经细胞瘤这是一个假名Rosette.

更多相关视频

Tumor Treating Field Therapy in Combination with Bevacizumab for the Treatment of Recurrent Glioblastoma

Tumor Treating Field Therapy in Combination with Bevacizumab for the Treatment of Recurrent Glioblastoma

Published on: October 27, 2014

Generation of CAR T Cells for Adoptive Therapy in the Context of Glioblastoma Standard of Care

Generation of CAR T Cells for Adoptive Therapy in the Context of Glioblastoma Standard of Care

Published on: February 16, 2015

相关概念视频

Treatment Resistant Cancers

Treatment Resistant Cancers

Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...